Idera Pharmaceuticals Presents New Pre-Clinical Data

Idera Pharmaceuticals (NASDAQ:IDRA) reported new pre-clinical data from its ongoing IMO-2125 development program.
As quoted in the press release:

In the poster presentation entitled, “Intratumoral IMO-2125 Treatment in Combination with Anti-CTLA4 mAB Induces Durable Anti-Tumor Reponses Associated with Tumor-Specific Memory in Preclinical Studies,” presented by Daqing Wang, Ph.D., Principal Scientist & Group Leader, Idera Pharmaceuticals, demonstrated that intratumoral injections of IMO-2125 enhance anti-tumor responses in combination with CTLA4 blockade. Further this study demonstrated the combination of IMO-2125 and anti-CTLA4 achieves prolonged, durable anti-tumor effect.
In this study, mice whose tumors completely regressed survived more than one year after the combination treatment was administered. These animals maintained anti-tumor responses upon tumor re-challenge indicative of memory T-cell induction by the combination of IMO-2125 and anti-CTLA4.

Click here to read the full press release.

Source: globenewswire.com